You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Phase4 Partners Limited | 1,065,447 | 0 | 1,065,447 | 0 | 1,065,447 | 9.56% |
| Phase4 Ventures III | 1,065,447 | 0 | 1,065,447 | 0 | 1,065,447 | 9.56% |
| Phase4 Ventures III GP | 1,065,447 | 0 | 1,065,447 | 0 | 1,065,447 | 9.56% |
| Phase4 Ventures III General Partner Limited | 1,065,447 | 0 | 1,065,447 | 0 | 1,065,447 | 9.56% |
| Dr. Alastair McKinnon | 0 | 1,065,447 | 0 | 1,065,447 | 1,065,447 | 9.56% |
| Denise Scots-Knight, Ph.D | 0 | 1,065,447 | 0 | 1,065,447 | 1,065,447 | 9.56% |
| Charles Sermon | 0 | 1,065,447 | 0 | 1,065,447 | 1,065,447 | 9.56% |
Page 1 of 11 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*
ALBIREO PHARMA, INC.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
01345P 106
(CUSIP Number)
Charles Sermon
Phase4 Partners Limited
1 Cavendish Place
London W1G 0QF, United Kingdom
Telephone: +44 0 20 3036 0050
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
January 30, 2018
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Albireo Pharma Inc. (NASDAQ:ALBO)
Follow Albireo Pharma Inc. (NASDAQ:ALBO)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 11
